In vivo imaging of proteasome inhibition using a proteasome‐sensitive fluorescent reporter
Authors:
Open Access
- 7 June 2012
- journal article
- research article
- Published by Wiley in Cancer Science
- Vol. 103 (9) , 1730-1736
Abstract
A proteasome degrades numerous regulatory proteins that are critical for tumor growth and is therefore recognized as a promising anticancer target. Determining proteasome activity in the tumors of mice bearing xenografts is essential for the development of novel proteasome inhibitors. We developed a system for in vivo imaging of proteasome inhibition in the tumors of living mice, using a proteasome-sensitive fluorescent reporter, ZsProSensor-1. This reporter consists of a green fluorescent protein, ZsGreen, fused to mouse ornithine decarboxylase, which is degraded by the proteasome without being ubiquitinated. In stably transfected cells expressing ZsProSensor-1, the fluorescent reporter was rapidly degraded under steady-state conditions, whereas it was stabilized in the presence of proteasome inhibitors. Subcutaneous inoculation of the transfected cells into nude mice resulted in tumor formation. When the proteasome inhibitor bortezomib was intravenously administered to mice bearing these tumors, the ZsProSensor-1 protein accumulated in the tumors and emitted a fluorescent signal in a dose-dependent manner. Robust fluorescence was sustained for 3 days and then gradually decreased to baseline levels within 15 days. Intravenous administration of bortezomib also showed potent antitumor activity. In contrast, oral administration of bortezomib did not result in fluorescent protein accumulation in tumors or exhibit any antitumor activity. These results indicate that in vivo imaging using the ZsProSensor-1 fluorescent protein can be used as an indicator of antitumor activity and will be a powerful tool for the development of novel proteasome inhibitors.Keywords
This publication has 26 references indexed in Scilit:
- Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human CancerCancer Research, 2010
- CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomibBlood, 2008
- Image-Based Screening for the Identification of Novel Proteasome InhibitorsSLAS Discovery, 2007
- Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomibMolecular Cancer Therapeutics, 2006
- Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of Advanced Multiple Myeloma With BortezomibJournal of Clinical Oncology, 2006
- Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myelomaBlood, 2005
- A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from BortezomibCancer Cell, 2005
- Proteasome Inhibitor PS-341 Induces Apoptosis through Induction of Endoplasmic Reticulum Stress-Reactive Oxygen Species in Head and Neck Squamous Cell Carcinoma CellsMolecular and Cellular Biology, 2004
- The 26S Proteasome: A Molecular Machine Designed for Controlled ProteolysisAnnual Review of Biochemistry, 1999
- Role of the Ubiquitin-Proteasome Pathway in Regulating Abundance of the Cyclin-Dependent Kinase Inhibitor p27Science, 1995